Bivalirudin

Bivalirudin is a synthetic 20-amino acid peptide that directly inhibits thrombin through a unique bivalent mechanism. The compound was rationally designed based on hirudin, the potent thrombin inhibitor from medicinal leeches, incorporating both active site binding and exosite-1 binding elements connected by a tetraglycine spacer.

The N-terminal D-Phe-Pro-Arg-Pro sequence binds to thrombin's active site, while the C-terminal sequence (derived from hirudin residues 53-64) binds to thrombin's anion-binding exosite-1. This bivalent interaction provides high affinity and specificity for thrombin. Uniquely, once bound, thrombin slowly cleaves bivalirudin at the Arg-Pro bond, gradually restoring enzymatic activity - a self-limiting anticoagulant effect.

Clinically, bivalirudin is used as an anticoagulant during percutaneous coronary intervention (PCI) and as an alternative to heparin in patients with heparin-induced thrombocytopenia (HIT). Its short half-life (approximately 25 minutes) and predictable pharmacokinetics enable precise anticoagulation control without need for laboratory monitoring.

The compound's design exemplifies successful rational drug development from a natural product template, and its bivalent binding mechanism has informed development of other multi-domain inhibitors targeting proteins with multiple binding sites.